跳至主要内容
临床试验/ACTRN12624000976583
ACTRN12624000976583进行中(未招募)Unknown

Colorectal adenoma-carcinoma sequence rediscovered: interaction of human gut microbiota and local immune system in health and carcinogenesis in adult patients

Vilnius University Faculty of Medicine0 个研究点目标入组 54 人开始时间: 2024年8月12日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Exposure groups:
  • (1)Patients with histologically confirmed dysplastic colorectal lesion: early and advanced-adenoma, carcinoma in situ or adenocarcinoma (advanced adenomas are defined as those with high-grade dysplasia, villous or tubulovillous histology, equal to or greater than 1 cm in diameter);
  • (2)Adult patients;
  • (3)Written informed consent.
  • Control (healthy) group:
  • (1) Healthy patients (without any polypoid lesions found during screening colonoscopy)
  • (2) Adult patients;
  • (3)Written informed consent.

排除标准

  • Exclusion criteria
  • (1)Patients under the age of 18 years;
  • (2)Confirmed serrated (sessile serrated (SSA), traditional serrated adenomas (TSA)) or hyperplastic polyps or non-polypoid lesions;
  • (3)Signs of colorectal tumor obturating the lumen of the bowel which would limit complete colonoscopy;
  • (4)Suffer from other gastrointestinal tumors;
  • (5)Pregnancy;
  • (6)Previous colon resection;
  • (7)History of surgery disrupting gastrointestinal tract integrity;
  • (8)History of inflammatory bowel disease (ulcerative, Crohn’s, radiation-induced, or infectious colitis or other previous chronic inflammatory illnesses);
  • (9)Familial adenomatous polyposis (FAP) or other hereditary colon syndromes;
  • (10)Clinically significant immunodeficiency;
  • (11)Evidence of infection;
  • (12)During the last year patient had:
  • -suffered from Cl. difficile colitis or was a carrier of Cl. difficile; suffered from salmonellosis or other gastrointestinal infection;
  • -a long-term (> 6 months) use or recently completed therapeutic antibiotic course within the last month;
  • -corticosteroid and/or immunosuppressant therapy;
  • -received chemo- or radiation therapy in the abdomen and/or pelvis chemotherapy;
  • -regular use (> 3 months) of pre-/pro-/(sin)biotics and/or statins;
  • -a long-term (> 6 months) use of proton pump inhibitors;
  • (13)Patients who cannot undergo colonoscopy on time and cannot cooperate fully.

研究者

发起方
Vilnius University Faculty of Medicine

相似试验

进行中(未招募)
不适用
Patients on fluorouracil and folinic acid chemotherapy: a cohort study focused on oral mucositis.Chemotherapy induced oral mucositisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12609000339257Sao Paulo University25
进行中(未招募)
1 期
Alternating chemotherapy plus cetuximab to allow resection of metastases from a colorectal cancer that is wild-type KRAS and BRAF - a randomised phase II trial - Nordic 7.6Metastatic colorectal cancer with wild-type KRAS and BRAFMedDRA version: 14.1 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-004188-65-SEOdense University Hospital180
进行中(未招募)
不适用
Colorectal cancer cohort study (COLO-COHORT)Colorectal neoplasia, colorectal cancerColorectal neoplasiaCancer
ISRCTN17473023South Tyneside and Sunderland NHS Foundation Trust15,000
尚未招募
Unknown
To Study Colorectal Adenocarcinoma
CTRI/2024/02/062722Jawaharlal Nehru Medical College
尚未招募
Unknown
Verification of Colorectal Cancer Recurrence Prediction and Screening Capability Through Methylation Analysis of DNA in Plasma of SETOCHI Study ParticipantsColorectal Cancer
JPRN-UMIN000053122Kawasaki Medical School452